



A Norwegian biotech growth ambitions

September 19, 2024
Pareto Healthcare Conference

CEO Michael Akoh
CFO Børge Sørvoll



Overview

A Norwegian biotech with growth ambitions

World class products

- Novel enzymes for biomanufacturing and molecular research/diagnostics
- Value of products supported by numerous publications
- Strong reputation in Molecular Tools and Biomanufacturing segments
- Net Promoter Score = 84

The Market

- Targeting segments with high growth potential (MDx & CGT)
- Customers are life science tools, CDMO, Pharma and Biotech companies
- Global nature with direct sales channels in the US (45%) & Europe (50%) ROW (5%)

Organisation


- 53 employees, HQ in Tromsø, Norway
- Experienced management team committed to creating a strong culture centered on commercialization of innovative solutions
- World class R&D team, strong and excellent manufacturing capabilities
- ISO13485 and GMP compliance

Strong Financials

- Margins > 90% on all products
- Sales of 119 MNOK (2023) and generating profit
- Recurring revenue streams potential – sticky business
- No debt – 240 MNOK in Cash reserve
- Track record of 30yrs
- Listed on the Norwegian Stock Exchange

B2B Value chain

Biomanufacturing and Molecular Tools customers



Best-in-class Enzymes

Custom and OEM solutions – to meet customer's needs

Biomanufacturing (Therapeutics)

Viral vector, gene therapy and protein production

Removal of nucleic acids during protein production, vaccine manufacturing and viral vector preparation.



SAN HQ
SAN HQ GMP



M-SAN HQ

Molecular Workflows (Research & Molecular Diagnostics)

Sample Isolation

Ensure free nucleic acids, readily available for amplification, by removal of interfering proteins.



ArcticZymes Proteinase

Enrichment

Increase ability to detect your target, by removal of unwanted nucleic acids and carry-over contamination



HL-dsDNase



Cod UNG



HL-SAN



dsDNase

Amplification

Perform sensitive amplification of your target with isothermal amplification (i.e., LAMP) or PCR



IsoPol® Polymerases



AZtaq™ DNA
Polymerase




AZscript™ Reverse
Transcriptase



T7 Polymerase

Modification and
Downstream Analysis

Accurate and reliable analysis by Sanger sequencing or NGS



Shrimp Alkaline
Phosphatase



T4 DNA Ligase



Exonucleases




R2D Ligase

SAN - Probably the best nuclease portfolio on the market

The *right* nuclease for the *right* application

- A single nuclease cannot meet the diverse demands of viral vector bioprocessing
- A diverse range of nucleases is essential - there is no “one size fits all” solution in this market
- Our **M-SAN** nuclease is optimized for low-salt environments (~150 mM), ideal for Lenti vector production
- **SAN HQ GMP** is designed for high-salt conditions, typically around 500 mM or more, making it perfect for AAV vector production
- ArcticZymes offers one of the most versatile nuclease portfolios, covering the full spectrum of viral vector manufacturing needs
- Looking ahead, we will continue to innovate by launching two new GMP-grade nucleases within the next 12 months, expanding our leadership in the market



Strategic priorities

Building a platform for long term growth – the journey has started

Short Term

1

Market driven transformation

Excellence in commercialization

Partnerships – sales channels, CDMO, innovation

Scientific marketing (Publications, talks)

2

GMP upgrade of current unique enzymes

Ability to expand usage in more drug development phases
2 new GMP nucleases plus an ELISA kit in development

3

Relaunch of current Molecular tools enzymes

Application data and positioning

Long Term

1

Build advanced therapies biomanufacturing pipeline

RNA enzymes & NextGen AI SAN

2

Develop/commercialize new Molecular Tools enzymes

Sample prep, amplification and synthetic biology

3

M&A Opportunities

Fast track to building complete portfolio

Strengthen manufacturing capabilities

Stronger commercial channels and reach

Thank you

